Search Results

Stanford researchers have developed a test that may help screen for cardiotoxicity in new chemotherapy drugs.

Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. A Stanford study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.

The developmental biologist was honored for helping to decode how Wnt signaling proteins affect embryonic development, cancer and the activity of tissue-specific adult stem cells that repair damage after injury or disease.

The work extends research by Stanford scientists who found that blocking CD47 might be useful in treating human cancer.

Monitoring cancer DNA in blood can predict recurrence and prognosis and drive treatment decisions. A Stanford study of 92 lymphoma patients suggests similar techniques may work for other tumors.

Kara Davis, Melissa Mavers and Liora Schultz awarded St. Baldrick’s Foundation grants.

Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.

Doxorubicin is a chemotherapy drug used to treat many cancers, but it causes serious heart damage in some patients. Heart muscle cells made from the skin cells of breast cancer patients can be used to study this phenomenon.

People with cancer have tumor DNA in their blood. A new way to quiet background “noise” in the blood sample allows researchers to sequence minute quantities of these molecules to improve diagnosis and treatment.

Researchers have identified a link between the expression of a cancer-related gene and cell-surface molecules that protect tumors from the immune system.